SFDA Approves Jascayd for Idiopathic Pulmonary Fibrosis Treatment
Riyadh:The Saudi Food and Drug Authority (SFDA) has approved the registration of Jascayd (nerandomilast) as a treatment for adult patients with idiopathic pulmonary fibrosis (IPF). This progressive lung disease is marked by the formation of fibrous sc…